Glenmark Pharmaceuticals Ltd

The company said that its Epinephrine Injection is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) manufactured by BPI Labs, LLC (NDA 205029). Epinephrine Injection is commonly used in emergency medical settings for the treatment of severe allergic reactions and other critical conditions. According to IQVIA sales data for the 12-month period ending October 2025, the Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) market recorded annual sales of approximately $67.6 million, indicating a sizeable opportunity in the US generics market. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, 'We are excited to announce the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial, growing our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. Glenmark Pharmaceuticals, the company, reported a 72.3% jump in consolidated net profit to Rs 610.25 crore on a 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25. Shares of Glenmark Pharmaceuticals rose 0.20% to Rs 2,042.70 on the BSE. Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch of Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial. Glenmark's Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) of BPI Labs, LLC, NDA 205029. Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 2030, up 1.9% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.6% on the day, quoting at 26122.1. The Sensex is at 85390.89, up 0.54%. Glenmark Pharmaceuticals Ltd has gained around 10.18% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 1.78% in last one month and is currently quoting at 22751.25, up 0.62% on the day. The volume in the stock stood at 4.29 lakh shares today, compared to the daily average of 6.81 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 2037, up 2.12% on the day. Glenmark Pharmaceuticals Ltd is up 30.92% in last one year as compared to a 9.97% jump in NIFTY and a 1.42% jump in the Nifty Pharma index.The PE of the stock is 38.18 based on TTM earnings ending September 25.Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd is up for a fifth straight session today. The stock is quoting at Rs 1979, up 0.2% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is down around 0.14% on the day, quoting at 26010.15. The Sensex is at 85166.94, down 0.12%. Glenmark Pharmaceuticals Ltd has gained around 5.89% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 0.68% in last one month and is currently quoting at 22808.7, down 0.42% on the day. The volume in the stock stood at 1.52 lakh shares today, compared to the daily average of 11.36 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 1982.6, down 0.03% on the day. Glenmark Pharmaceuticals Ltd is up 27.57% in last one year as compared to a 5.44% jump in NIFTY and a 2.05% jump in the Nifty Pharma index.The PE of the stock is 37.86 based on TTM earnings ending September 25.Powered by Capital Market - Live

The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Leucovorin Calcium for Injection, 350 mg/vial, marketed by Hospira Inc. Glenmark stated that distribution of the product will begin in December 2025. Citing IQVIA sales data for the 12 months ending October 2025, the company said the U.S. market for Leucovorin Calcium for Injection, 350 mg/vial recorded annual sales of approximately $16.8 million, including the brand product and all available therapeutic equivalents. Glenmark emphasized that its Leucovorin Calcium for Injection USP, 350 mg/vial is approved only for the indications listed on its FDA-approved label and is not marketed for all RLD indications. Marc Kikuchi, President & Business Head, North America said, 'We are pleased to announce the upcoming launch of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial, further expanding our portfolio of products within the institutional channel, while also strengthening our commitment to bring to market quality and affordable alternatives for patients.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. Glenmark Pharmaceuticals, the company, reported a 72.3% jump in consolidated net profit to Rs 610.25 crore on a 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25. The counter rose 0.24% to Rs 1,957.60 on the BSE. Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the upcoming launch of Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial. Glenmark's Leucovorin Calcium for Injection USP, 350 mg/vial Single-Dose Vial is bioequivalent and therapeutically equivalent to the reference listed drug, Leucovorin Calcium for Injection, 350 mg/vial, of Hospira, Inc. [NDA 008107]. Glenmark will begin distribution in December 2025.Powered by Capital Market - Live

According to the company's exchange filing, the inspection was conducted between 24 November and 28 November 2025. Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. Glenmark Pharmaceuticals, the company, reported a 72.3% jump in consolidated net profit to Rs 610.25 crore on a 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25. The counter rose 0.01% to Rs 1,947.35 on the BSE. Powered by Capital Market - Live

Glenmark Pharmaceuticals announced that the U.S. Food and Drug Administration (U.S. FDA) completed Pre-Approval Inspection at the Company's formulations manufacturing facility in Chhatrapati Sambhajinagar (Aurangabad). The inspection was carried out from 24 November to 28 November 2025, and concluded with zero 483 observations. Powered by Capital Market - Live

Glenmark Pharmaceuticals Ltd is up for a third straight session today. The stock is quoting at Rs 1941, up 1.03% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.18% on the day, quoting at 26251.5. The Sensex is at 85859.63, up 0.29%. Glenmark Pharmaceuticals Ltd has gained around 6.94% in last one month. Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has gained around 2.75% in last one month and is currently quoting at 22862.35, down 0% on the day. The volume in the stock stood at 9.89 lakh shares today, compared to the daily average of 12.05 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 1952, up 0.86% on the day. Glenmark Pharmaceuticals Ltd is up 29.82% in last one year as compared to a 9.77% jump in NIFTY and a 5.22% jump in the Nifty Pharma index.The PE of the stock is 36.84 based on TTM earnings ending September 25.Powered by Capital Market - Live

The inspection at the Monroe facility was conducted from 9 June to 17 June 2025. Glenmark said that with this positive development, it will restart commercial manufacturing at the facility. Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. Glenmark Pharmaceuticals, the company, reported a 72.3% jump in consolidated net profit to Rs 610.25 crore on a 76.6% increase in revenue from operations to Rs 6,003.79 crore in Q2 FY25. Powered by Capital Market - Live